Sugi Predict

Sugi Predict / Compounds / SCHEMBL278668

SCHEMBL278668

SCHEMBL278668

CC(C)N1CCN(c2ccc(Cl)nn2)CC1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.61
▸ BPTF Q12830 1/20 0.57
▸ OGA O60502 1/20 0.56
▸ LMNA P02545 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ PANK3 Q9H999 5/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.50
▸ HTT P42858 1/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744812 0.94 CYP1A2 (0.63) CYP1A2BPTFOGALMNAALDH1A1
SCHEMBL9493167 0.84 CYP1A2 (0.54) CYP1A2BPTFOGALMNAALDH1A1
SCHEMBL22692189 0.81 OGA (0.57) CYP1A2OGAALDH1A1HRH3HTT
SCHEMBL257823 0.80 CYP1A2 (0.67) CYP1A2BPTFLMNAALDH1A1HTT
SCHEMBL18291486 0.79 HRH3 (0.50) CYP1A2OGAALDH1A1HRH3MAPT
SCHEMBL20255262 0.79 OGA (0.58) CYP1A2OGAALDH1A1HRH3MAPT
SCHEMBL20045994 0.79 HRH3 (0.50) CYP1A2OGAALDH1A1PANK3HRH3
SCHEMBL3972252 0.79 MAPT (0.50) OGALMNAALDH1A1HRH3KMT2A
SCHEMBL9990416 0.77 CYP1A2 (0.88) CYP1A2BPTFLMNAALDH1A1PANK3
SCHEMBL29845748 0.77 CYP1A2 (0.96) CYP1A2BPTFLMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 — — US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 — — US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 — — US disclosed
US-20120115876-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES WARSHAKOON NAMAL CHITHRANGA (US) 2012-05-10 — — US disclosed
US-8133894-B2 N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones AKEBIA THERAPEUTICS INC. (US) 2012-03-13 — — US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 — — EP disclosed
US-20100305097-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES WARNER CHILCOTT COMPANY, LLC 2010-12-02 — — US disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 — — EP disclosed
US-7790748-B2 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones WARNER CHILCOTT COMPANY, LLC (US) 2010-09-07 — — US disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 — — US disclosed
CN-101218206-A Histamine H3 receptor antagonists NOVO NORDISK AS (DK) 2008-07-09 — — CN disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 — — EP disclosed
US-20070270407-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2007-11-22 — — US disclosed
US-20070238722-A1 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2007-10-11 — — US disclosed
US-7247632-B2 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2007-07-24 — — US disclosed
US-7247648-B2 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2007-07-24 — — US disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 — — WO disclosed
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2004-05-20 — — US disclosed
US-20040097559-A1 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones WARNER CHILCOTT COMPANY, LLC 2004-05-20 — — US disclosed
US-20040097559-A1 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones WARNER CHILCOTT COMPANY, LLC 2004-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097559-A1 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, TLR1, CYP51A1 CYP1A2 51/4885BPTF 3304/4885OGA 3482/4885
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 CYP1A2 4518/4885BPTF 1244/4885OGA 3751/4885
US-20120115876-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES IL17A, IFNG, CD4 CYP1A2 32/4885BPTF 1634/4885OGA 2922/4885
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, CYP51A1, CD4 CYP1A2 22/4885BPTF 2560/4885OGA 3090/4885
US-20070270407-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, IFNG, CD4 CYP1A2 20/4885BPTF 2115/4885OGA 2636/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 CYP1A2 4518/4885BPTF 1244/4885OGA 3751/4885
US-20070238722-A1 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, IFNG, TLR6 CYP1A2 59/4885BPTF 2889/4885OGA 3050/4885
US-20100305097-A1 N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES IL17A, IFNG, CD4 CYP1A2 32/4885BPTF 1634/4885OGA 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.